CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled
Drug / intervention
MK-7252 +1 moredrug
Likely dose
MK-7252 1 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03326986
NCT03326986Phase 1Completed
CompareCT.gov

A Single Ascending Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-7252 in Healthy Subjects

Merck Sharp & Dohme LLC·interventional·Posted Oct 31, 2017·Updated Jan 9, 2020

In Brief

A Phase 1 clinical trial evaluating MK-7252 and Placebo for Pharmacokinetics and Cancer. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of MK-7252 in healthy adults. Participants receive ascending doses of MK-7252 over five treatment periods. Each treatment period is separated by a 7-day washout period. Upon review of the interim safety and preliminary PK data of human exposure to date, Protocol Amendment 3 includes a third panel of participants, Panel C, to assess the PK of higher doses of MK-7252 and to assess the food effect of MK-7252.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharmacokinetics, Cancer
CountriesBelgium
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 31, 2017
Enrollment StartNov 10, 2017
Primary CompletionDec 17, 2018
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.7 years ago

Interventions

MK-7252drug

1 mg/mL or 20 mg/mL of powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL

Placebodrug

Placebo powder for oral suspension administered with a water volume that brings the total ingested volume to approximately 240 mL